A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Trial Profile

A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Brain metastases; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 27 May 2016 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
    • 27 May 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top